Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Principal Accounting Officer | March 04, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Monte Rosa Therapeutics, Inc.
Report date March 04, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,554 |
Reported balance
After 2026-03-04 transaction · row 1
1 source rowRow 1 · 2026-03-04 · Sale · Disposed 139 · Balance 22,554 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 22:24 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 139 | $17.96 | $2,496.44 |
DisclosureSEC source: 0001193125-26-094296 · ownership.xml · nonDerivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,554 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:02 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionStock Option (Right to Buy) · Derivative | 536 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001193125-26-085677 · ownership.xml · derivative · entry 6 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 536 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:02 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 536 | $17.50 | $9,380.00 |
DisclosureSEC source: 0001193125-26-085677 · ownership.xml · nonDerivative · entry 4 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,693 Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 22:02 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionCommon Stock | 536 | $13.41 | $7,187.76 |
DisclosureSEC source: 0001193125-26-085677 · ownership.xml · nonDerivative · entry 3 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 22:02 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,164 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001193125-26-085677 · ownership.xml · derivative · entry 5 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536 Underlying: Common Stock · 25,164 shares Expires 2032-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 22:02 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 25,164 | $18.10 | $455,506.15 |
DisclosureSEC source: 0001193125-26-085677 · ownership.xml · nonDerivative · entry 2 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,693 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.06 to $18.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 22:02 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | Exercise / conversionCommon Stock | 25,164 | $13.41 | $337,449.24 |
DisclosureSEC source: 0001193125-26-085677 · ownership.xml · nonDerivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2026 Filed Jan 5, 2026 21:04 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 1,039 | $15.17 | $15,761.63 |
DisclosureSEC source: 0001193125-26-002390 · ownership.xml · nonDerivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,693 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 2,062 | $4.45 | $9,174.46 |
DisclosureSEC source: 0000950170-25-081637 · ownership.xml · nonDerivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,732 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.34 to $4.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 53,400 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0000950170-25-002103 · ownership.xml · derivative · entry 2 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,400 Underlying: Common Stock · 53,400 shares Expires 2035-01-01 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantCommon Stock | 11,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-002103 · ownership.xml · nonDerivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,794 F1 · shares: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F1 · price: Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 1, 2026, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 05, 2024 Filed Jul 9, 2024 20:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 1,610 | $3.83 | $6,166.46 |
DisclosureSEC source: 0000950170-24-082416 · ownership.xml · nonDerivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,944 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.83 to $3.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:10 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | SaleCommon Stock | 1,207 | $4.04 | $4,875.80 |
DisclosureSEC source: 0000950170-24-069310 · ownership.xml · nonDerivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,554 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.0111 to $4.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 35,900 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000765 · doc4.xml · derivative · entry 2 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2034-01-01 F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:15 UTC | Monte Rosa Therapeutics, Inc. GLUE · Entity 4828 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001209191-24-000765 · doc4.xml · derivative · entry 1 Dunn Edmund · CIK 0001989401 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on October 2, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.